Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -39.33M | -21.78M | -32.85M | -46.66M | -43.94M |
Total Depreciation and Amortization | 606.00K | 601.00K | 596.00K | 595.00K | 605.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 25.56M | 23.29M | 21.04M | 16.02M | 13.48M |
Change in Net Operating Assets | 2.46M | -68.78M | 1.13M | 8.72M | -7.40M |
Cash from Operations | -10.70M | -66.67M | -10.09M | -21.32M | -37.25M |
Capital Expenditure | -35.00K | -263.00K | -35.00K | -33.00K | -27.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 14.88M | -29.13M | 58.66M | -2.41M | 68.64M |
Cash from Investing | 14.85M | -29.40M | 58.62M | -2.44M | 68.62M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 290.00K | 555.00K | 98.50M | 979.00K | 811.00K |
Repurchase of Common Stock | -4.42M | -456.00K | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -24.46M | 27.47M | -27.27M | 40.91M | -14.44M |
Cash from Financing | -28.59M | 27.57M | 71.23M | 41.89M | -13.63M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -24.44M | -68.50M | 119.76M | 18.13M | 17.73M |